FIELD: medicine, pharmacy. SUBSTANCE: invention relates to methods of use of antifibrin antibody for inhibition of thrombus formation in vitro and to pharmaceutical composition and set containing pharmaceutical composition for use in these methods. Method involves the use of monoclonal MN-1 antibody produced by hybridoma AFSS 9739. Invention ensures to inhibit thrombus formation in the point of blood vessel damage. EFFECT: enhanced effectiveness of agent. 24 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOASSAY OF SOLUBLE FIBRIN POLYMERS | 1994 |
|
RU2173347C2 |
| THROMBIN-BINDING MOLECULES OF ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2642276C2 |
| FIBRINOGEN CONTENT ANALYSIS | 2012 |
|
RU2619256C2 |
| ANTITHROMBOTIC PREPARATION AND METHOD OF PROPHYLAXIS AND TREATMENT OF THROMBOSIS | 2002 |
|
RU2205027C1 |
| NEW ANTIBODIES AGAINST XI FACTOR AND THEIR APPLICATIONS | 2017 |
|
RU2758160C2 |
| USING MATRIC METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC THERAPY | 2008 |
|
RU2489163C2 |
| POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | 2019 |
|
RU2778566C1 |
| NOVEL HUMANISED ANTIBODIES TO FACTOR XI WITH ANTITHROMBOTIC AND ANTI-INFLAMMATORY ACTION AND USE THEREOF | 2020 |
|
RU2817219C2 |
| FIBRIN/FIBRINOGEN-BINDING CONJUGATE | 2001 |
|
RU2279890C2 |
| TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF | 2013 |
|
RU2671955C2 |
